Refractory Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase II Study of BAY 43-9006 in Relapsed Chronic Lymphocytic Leukemia
Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. This phase II trial is studying how well sorafenib works in treating patients with relapsed chronic lymphocytic leukemia.
Status | Terminated |
Enrollment | 5 |
Est. completion date | May 2011 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed chronic lymphocytic leukemia (CLL) by NCI-WG immunophenotype and blood criteria - Documentation of current or prior peripheral blood (PB) or bone marrow (BM) immunophenotype compatible with CLL - Patients who currently do not have > 5,000/mm³ absolute lymphocytosis are eligible if they have previously met PB lymphocytosis criteria and have a current immunophenotype documenting monoclonal B lymphocytosis morphologically and immunophenotypically compatible with CLL - Intermediate-risk (Rai stage I or II) or high-risk (Rai stage III or IV) disease, including any of the following: - Rai stage I disease with lymphocytosis and enlarged nodes - Rai stage II disease with lymphocytosis plus splenomegaly and/or hepatomegaly (nodes positive or negative) - Rai stage III disease with lymphocytosis plus anemia - Rai stage IV disease with lymphocytosis and thrombocytopenia - Must require treatment with active disease, experiencing disease related symptoms, or having deterioration of blood counts, meeting = 1 of the following criteria: - Presence of = 1 of the following disease-related symptoms: - Weight loss > 10% within the past 6 months - Extreme fatigue (i.e., ECOG performance status 2: cannot work or unable to perform usual activities) - Fever > 100.5°F for 2 weeks without evidence of infection - Night sweats without evidence of infection - Evidence of progressive marrow failure, as manifested by worsening of anemia (hemoglobin < 10 g/dL), thrombocytopenia (platelet count < 100,000/mm³), and/or neutropenia (neutrophil count < 2,000/mm³) - Massive (i.e., > 6 cm below left costal margin) or progressive splenomegaly or discomfort from splenomegaly - Massive nodes or clusters (i.e., > 10 cm in longest diameter), progressive adenopathy, or discomfort from lymphadenopathy - Deterioration of blood counts and/or progressive lymphocytosis, with an increase of = 10% documented over a 2-month period OR an anticipated doubling time < 6 months - Relapsed disease - Must receive at least 1, but no more than 3, prior chemotherapy regimens with any cytotoxic agent or antibody therapy - No fludarabine refractory disease - Responded to prior fludarabine without relapse or disease progression for at least 6 months - Patients with a history of Coombs-positive hemolytic anemia are eligible provided recovery from treatment of hemolysis and off steroids - No stage 0 CLL - No known CNS involvement - Life expectancy > 6 months - ECOG performance status 0-2 OR Karnofsky performance status 70-100% - Absolute neutrophil count = 1,000/mm³ - Platelets = 30,000/mm³ - Bilirubin = 2 mg/dL - AST/ALT = 2.5 times upper limit of normal (ULN) - Creatinine = 1.5 times ULN OR creatinine clearance = 60 mL/min (for patients with creatinine levels above normal) - No currently active second malignancy - Not pregnant or nursing - Negative pregnancy test - Fertile patient must use effective contraception prior to and during study participation - No uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg on 2 different measurements at least 1 day apart with either systolic or diastolic number meeting this definition - Patients may later enter the study, if they have achieved stable BP (i.e., < 140/90 mm Hg) on a regimen of = 2 drugs after 6-8 weeks of therapy - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib - No uncontrolled intercurrent illness including, but not limited to, any of the following: - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness or social situations that would limit compliance with the study requirements - No active infection requiring systemic antibiotics - No evidence of bleeding diathesis - No evidence of bowel perforation or obstruction risk - No swallowing dysfunction leading to difficulty taking the study drug - See Disease Characteristics - Recovered from prior therapy - At least 2 weeks since prior antibiotic therapy - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy - At least 12 weeks since prior monoclonal antibody - Concurrent warfarin for anticoagulation allowed provided all of the following are met: - On a stable therapeutic dose - INR = 3 - No active bleeding or pathological condition that carries high-risk of bleeding - No prior MAPK signaling inhibitor agents or anti-angiogenesis agents - No concurrent combination anti-retroviral therapy for HIV-positive patients - No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort) - No other concurrent investigational agents |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago Comprehensive Cancer Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | Objective response is defined as a complete (CR) or partial (PR) remission. Complete remission is defined as no evidence of chronic lymphocytic leukemia (CLL) in marrow with normal hematopoiesis and no palpable lymphadenopathy. Partial remission is defined as improvement in blood counts from baseline with >50% reduction in lymph nodes on examination. These are definitions from the CLL International Working Group (IWG). | Up to week 25 | No |
Primary | Time to Disease Progression | Time to disease progression will be defined as the time from treatment start until disease progression and will be evaluated using the Kaplan-Meier estimator. Those who do not progress will be censored at the time that they were last known to be progression free. | Up to 5.5 years | No |
Primary | Overall Survival | Overall survival will be defined as time from the start of treatment until death from any cause and will be evaluated using the Kaplan-Meier estimator. | Up to 5.5 years | No |
Secondary | Changes in Mean Microvessel Density From Baseline to Week 25 | Mean microvessel density will serve as a marker of angiogenesis (other markers includes hot spot density). Will be examined using random-effects linear models. | Baseline and week 25 | No |
Secondary | Changes in Vascular Endothelial Growth Factor (VEGF) From Baseline to Week 25 | Changes in VEGF levels (post-pretreatment) will be assessed. A negative value indicates a decrease with treatment. | Baseline and week 25 | No |
Secondary | Changes in Plasma Level of Interleukin-8 (IL-8) From Baseline to Week 25 | The change (post-pretreatment) will be calculated and tested using a paired t test. A negative value indicates a decrease with treatment. | Baseline and week 25 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03045328 -
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Active, not recruiting |
NCT01369849 -
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00006226 -
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00005803 -
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00003196 -
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
|
N/A | |
Active, not recruiting |
NCT04230304 -
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
|
Phase 2 | |
Recruiting |
NCT04007029 -
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04892277 -
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Active, not recruiting |
NCT04578600 -
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
|
Phase 1 | |
Completed |
NCT02240719 -
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
|
Phase 1 | |
Completed |
NCT01441882 -
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT01408043 -
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
|
N/A |